INVESTORS & MEDIA
Corporate Governance
| Date | Name | Title | Filing | Type | Shares Traded | Price | Total Held |
|---|---|---|---|---|---|---|---|
| Dec 17, 2013 |
Director, Pres Regeneron Labs
|
Director, Pres Regeneron Labs | Form 4 | Other acquisition or disposition | -- | -- | 5,591 |
| Dec 13, 2013 |
Director, Pres Regeneron Labs
|
Director, Pres Regeneron Labs | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 150,000 | -- | 246,736 |
| Dec 13, 2013 |
Director, Pres Regeneron Labs
|
Director, Pres Regeneron Labs | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 203,204 | -- | 203,204 |
| Dec 13, 2013 |
Director, Pres Regeneron Labs
|
Director, Pres Regeneron Labs | Form 4 | Other acquisition or disposition | -- | -- | 5,591 |
| Dec 12, 2013 |
Director, Pres Regeneron Labs
|
Director, Pres Regeneron Labs | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 9,599 | -- | -- |
| May 08, 2013 |
Director, President Regeneron Laboratori
|
Director, President Regeneron Laboratori | Form 4 | Other acquisition or disposition | -- | -- | 5,591 |
| May 06, 2013 |
Director, President Regeneron Laboratori
|
Director, President Regeneron Laboratori | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 192,308 | -- | -- |
| May 06, 2013 |
Director, President Regeneron Laboratori
|
Director, President Regeneron Laboratori | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 9,599 | -- | 9,599 |
| Dec 21, 2012 |
Director, EVP CSO Pres Regen Res Labs
|
Director, EVP CSO Pres Regen Res Labs | Form 4 | Other acquisition or disposition | -- | -- | 5,534 |
| Dec 19, 2012 |
Director, EVP CSO Pres Regen Res Labs
|
Director, EVP CSO Pres Regen Res Labs | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 10,537 | -- | -- |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.